companies

Orikami

Founded 2011
Employees 20+
Primary contact
Ridderstraat 29
6511 TM Nijmegen
Netherlands
+31 (0)24 301 0100
Links
https://www.orikami.ai/
Diseases & Conditions
Sections
Technologies
Orikami is specialized in applied data science and the development and implementation of digital biomarkers to enable personalized healthcare for people with chronic diseases. Digital biomarkers are defined as objective, quantifiable physiological and behavioral data that are collected and measured by means of digital devices such as portables, wearables, implantables or digestibles. The collected data is typically used to monitor, explain, influence and/or predict health-related outcomes.
Select partners: University of Twente, Amsterdam UMC, Radboud umc, ParkinsonNext, The MS Center Amsterdam, MS sherpa.
Select clients: Roche, Sanofi, Janssen, Biogen, Brainclinics, Pluryn, Vilans.
Founded 2011
Employees 20+
Primary contact
Ridderstraat 29
6511 TM Nijmegen
Netherlands
+31 (0)24 301 0100
Links
https://www.orikami.ai/
Diseases & Conditions
Sections
Technologies

Funding 💰

Total €600K
Select investors Healthy.Capital, CbusineZ

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Bold goal: Orikami is on a mission to improve 100 million lives before 2030 by access to personalized healthcare.
  • Academic approach: All the company's products have gone through a rigorous clinical validation process. 🔗
  • Clinical trials AND practice: Orikami's offering targets healthcare providers and life science companies, which could use it to enhance clinical trials and in clinical practice where it will help facilitate more accurate positioning of products and create an innovative approach to beyond-the-pill concepts for excellence in patient guidance. 🔗

Video ▶️

Awards & Recognitions 🏆

  • 2021 Best Digital Biomarker Company 🔗

Quotes 💬

“
Orikami has been a valuable partner in the design, development en delivery of our data backbone. In collaboration with our Vilans data scientists and engineers, the team has proven to be knowledgeable, very hands-on, and reliable. A constructive and pleasant co-operation.
— Vilans 🔗
“
Orikami develops practical solutions for healthcare with a robust and scientific approach in our joint digital biomarker initiative, I am looking forward to continue our collaboration.
— Ton Peters, Associate Director Evidence Generation Benelux, Janssen Pharmaceutica 🔗
“
In our view, Orikami is one of the Dutch digital health companies with great potential to improve healthcare. The entry of CbusineZ endorses our vision. It is crucial to involve healthcare professionals, patients and health insurers in the rollout of healthcare innovations.
— Douwe Jippes, managing partner at Healthy.Capital 🔗
“
We are very excited about this collaboration. With the help of Orikami's Digital Biomarkers, doctors gain a greatly improved insight into a patient's clinical picture. This gives them more prospects for action and enables them to optimize the treatment. This leads to better treatment outcomes and lower costs in the system.
— Rogier van der Hooft, Board of Directors of CbusineZ 🔗
Last update: August 17, 2022